Dees D Dustin, Spahn Kate J, Wagner Lynsey Smith, Greller Andrew, Paglia Danielle, Armour Micki D, Madsen Richard
Eye Care for Animals, 12419 Metric Blvd, Austin, TX, 78758, USA.
South Texas Veterinary Ophthalmology, 503 E. Sonterra Blvd, Suite 102, San Antonio, TX, 78258, USA.
Vet Ophthalmol. 2017 Nov;20(6):514-521. doi: 10.1111/vop.12461. Epub 2017 Feb 6.
To determine whether topical hypotensive medications prevent postoperative ocular hypertension (POH) after phacoemulsification.
52 client-owned dogs (88 eyes).
Diabetic and nondiabetic dogs having undergone phacoemulsification were included in this retrospective study. The control group received no ocular hypotensive medications. The treatment groups received latanoprost, dorzolamide, or dorzolamide/timolol, beginning immediately after surgery, for 2-week duration. IOPs were obtained at initial examination followed by 4 h, 24 h, 7 days, and 14 days postoperatively. POH was defined as an IOP above 20 mmHg (POH20) or 25 mmHg (POH25).
POH20 occurred in 33 of 87 eyes (37.93%), including 11 of 21 eyes (52.38%) in the control group, three of 23 eyes (13.04%) in the latanoprost group, eight of 15 eyes (53.33%) in the dorzolamide group, and 11 of 28 eyes (39.29%) in the dorzolamide/timolol group. Active treatment groups were compared to the control group, and the overall group effect was not significant (P = 0.11). POH25 occurred in 22 of 86 eyes (25.58%), including seven of 21 eyes (33.33%) in the control group, two of 23 eyes (8.70%) in the latanoprost group, five of 15 eyes (33.33%) in the dorzolamide group, and eight of 27 eyes (29.63%) in the dorzolamide/timolol group. Active treatment groups were compared to the control group, and the overall group effect was not significant (P = 0.31). Intraoperative use of intracameral tissue plasminogen activator significantly decreased the chances of POH25 (P = 0.0063).
The latanoprost group had a substantially lower percentage of POH 20 and POH25 compared to the control and other active treatment groups, although statistical significance was not achieved. Intraoperative intracameral tissue plasminogen activator decreased the incidence of POH25.
确定局部降压药物是否能预防白内障超声乳化术后的术后高眼压（POH）。
52只客户拥有的犬（88只眼）。
本回顾性研究纳入了接受白内障超声乳化术的糖尿病和非糖尿病犬。对照组未使用眼部降压药物。治疗组在手术后立即开始使用拉坦前列素、多佐胺或多佐胺/噻吗洛尔，持续2周。在初次检查时以及术后4小时、24小时、7天和14天测量眼压。POH定义为眼压高于20 mmHg（POH20）或25 mmHg（POH25）。
87只眼中有33只（37.93%）发生POH20，其中对照组21只眼中有11只（52.38%），拉坦前列素组23只眼中有3只（13.04%），多佐胺组15只眼中有8只（53.33%），多佐胺/噻吗洛尔组28只眼中有11只（39.29%）。将活性治疗组与对照组进行比较，总体组效应不显著（P = 0.11）。86只眼中有22只（25.58%）发生POH25，其中对照组21只眼中有7只（33.33%），拉坦前列素组23只眼中有2只（8.70%），多佐胺组15只眼中有5只（33.33%），多佐胺/噻吗洛尔组27只眼中有8只（29.63%）。将活性治疗组与对照组进行比较，总体组效应不显著（P = 0.31）。术中使用前房内组织纤溶酶原激活剂显著降低了发生POH25的几率（P = 0.0063）。
与对照组和其他活性治疗组相比，拉坦前列素组发生POH20和POH25的百分比显著较低，尽管未达到统计学显著性。术中前房内组织纤溶酶原激活剂降低了POH25的发生率。
